Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eribulin + ramucirumab
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
A combination therapy consisting of eribulin, a non-taxane synthetic microtubule inhibitor, and ramucirumab, a human IgG1 monoclonal antibody targeting VEGFR-2. Eribulin inhibits microtubule polymerization without affecting depolymerization, causing apoptosis through mitotic block at G2-M phase. It also alters the tumor microenvironment, exhibits anti-angiogenic properties, and decreases migration and invasiveness. Ramucirumab binds to VEGFR-2, preventing binding of VEGF ligands (VEGF-A, VEGF-C, and VEGF-D), thereby inhibiting endothelial cell proliferation, permeability, and migration.
- Brand names
- Cyramza (ramucirumab)Halaven (eribulin)
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on eribulin + ramucirumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eribulin + ramucirumab.